1. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study. (27th December 2021) Authors: Oliver, R.; Krueger, J.G.; Glatt, S.; Vajjah, P.; Mistry, C.; Page, M.; Edwards, H.; Garcet, S.; Li, X.; Dizier, B.; Maroof, A.; Watling, M.; el Baghdady, A.; Baeten, D.; Ionescu, L.; Shaw, S. Journal: British journal of dermatology Issue: Volume 186:Number 4(2022) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study. (1st April 2022) Authors: Oliver, R.; Krueger, J.G.; Glatt, S.; Vajjah, P.; Mistry, C.; Page, M.; Edwards, H.; Garcet, S.; Li, X.; Dizier, B.; Maroof, A.; Watling, M.; el Baghdady, A.; Baeten, D.; Ionescu, L.; Shaw, S. Journal: British journal of dermatology Issue: Volume 186:Number 4(2022) Page Start: 652 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗